CLDX
Q4 2026 EPS Estimate
$-1.02
Nov 9, 2026
Revenue Estimate
$725,750
FY2030E EPS$3.20

Analyst Sentiment

Wall St. Consensus
Buy
18 analysts·Moderate coverage
74
Score
17 Buy (94%)1 Hold (6%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1794%
Hold
16%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$40.00
-4.6%
Consensus
$60.50
+44.2%
Bull
$100.00
+138.4%
12-Month Target Range18 analysts
$40.00$60.50$100.00
Current $41.95Consensus
Current Price
$41.95
Upside to Consensus
$18.55

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+400.14%
EPS
FY2028
Rev+980.04%
EPS
FY2029
Rev+260.85%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$2M$11M$119M$430M$849M
Low$13,064$3M$14M$53M$104M
High$6M$29M$257M$952M$1.88B
EBITDA Avg$-2M$-11M$-119M$-430M$-849M
Low$-6M$-29M$-257M$-952M$-1.88B
High$-13,064$-3M$-14M$-53M$-104M
EBIT Avg$-2M$-11M$-119M$-430M$-849M
Low$-6M$-29M$-257M$-952M$-1.88B
High$-13,064$-3M$-14M$-53M$-104M
Net Income Avg$-285M$-301M$-320M$-32M$213M
Low$-303M$-359M$-324M$-81M$-30M
High$-268M$-243M$-80M$4M$548M
EPS Avg$-4.35$-4.35$-3.22$-0.47$3.20
Low$-4.56$-5.40$-4.87$-1.22$-0.45
High$-4.02$-3.66$-1.20$0.07$8.24
Analysts (Rev / EPS)9 / 910 / 911 / 105 / 45 / 4
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$801,583$1M$440,000$586,667$586,667$586,667
Low$310,290$394,161$170,322$227,096$227,096$227,096
High$1M$2M$709,677$946,237$946,237$946,237
EBITDA Avg$-801,583$-1M$-440,000$-586,667$-586,667$-586,667
Low$-1M$-2M$-709,677$-946,237$-946,237$-946,237
High$-310,290$-394,161$-170,322$-227,096$-227,096$-227,096
EBIT Avg$-801,583$-1M$-440,000$-586,667$-586,667$-586,667
Low$-1M$-2M$-709,677$-946,237$-946,237$-946,237
High$-310,290$-394,161$-170,322$-227,096$-227,096$-227,096
Net Income Avg$-84M$-83M$-80M$-77M$-82M$-85M
Low$-87M$-149M$-143M$-139M$-147M$-153M
High$-81M$-17M$-16M$-16M$-17M$-17M
EPS Avg$-1.07$-1.07$-1.03$-0.99$-1.05$-1.10
Low$-1.12$-1.92$-1.84$-1.79$-1.88$-1.97
High$-1.04$-0.22$-0.21$-0.20$-0.21$-0.22
Analysts (Rev / EPS)6 / 73 / 23 / 23 / 23 / 23 / 5

Earnings Surprises

Recent Analyst Actions

Aug 7, 2026Barclays
Celldex price target raised to $53 from $48 at Barclays
Target:$53.00
+27.5%from $41.56
Jul 29, 2026Wells Fargo
Celldex price target raised to $72 from $48 at Wells Fargo
Target:$72.00
+102.4%from $35.58
Jul 22, 2026Cantor Fitzgerald
Celldex price target lowered to $61 from $67 at Cantor Fitzgerald
Target:$61.00
+71.1%from $35.66
Jul 22, 2026Wells Fargo
Celldex price target lowered to $48 from $54 at Wells Fargo
Target:$48.00
+34.6%from $35.66
Jul 22, 2026Morgan Stanley
Celldex price target lowered to $40 from $44 at Morgan Stanley
Target:$40.00
+12.2%from $35.66
Jul 22, 2026Canaccord Genuity
Celldex price target lowered to $60 from $62 at Canaccord
Target:$60.00
+68.3%from $35.66
Jul 22, 2026Leerink Partners
Celldex price target lowered to $70 from $78 at Leerink
Target:$70.00
+96.3%from $35.66
Jul 20, 2026Guggenheim
Celldex price target raised to $100 from $90 at Guggenheim
Target:$100.00
+182.9%from $35.35
Jun 10, 2026UBS
Celldex price target raised to $45 from $38 at UBS
Target:$45.00
+49.0%from $30.21
May 13, 2026Wells Fargo
Celldex price target raised to $54 from $38 at Wells Fargo
Target:$54.00
+68.8%from $32.00
May 8, 2026Barclays
Celldex price target raised to $48 from $45 at Barclays
Target:$48.00
+44.1%from $33.32
Apr 20, 2026Barclays
Celldex upgraded to Overweight from Underweight at Barclays
Target:$45.00
+30.2%from $34.55
Dec 17, 2025Barclays
Celldex price target raised to $24 from $21 at Barclays
Target:$24.00
-10.0%from $26.68
Nov 11, 2025Barclays
Celldex price target lowered to $21 from $25 at Barclays
Target:$21.00
-7.4%from $22.67
Oct 13, 2025Barclays
Celldex initiated with an Underweight at Barclays
Target:$25.00
-6.6%from $26.77
Mar 20, 2025Morgan Stanley
Celldex initiated with an Overweight at Morgan Stanley
Target:$46.00
+131.4%from $19.88
Oct 29, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX)
Target:$80.00
+195.0%from $27.11
Sep 25, 2024Wells Fargo
Celldex upgraded to Overweight from Equal Weight at Wells Fargo
Target:$44.00
+22.2%from $36.02
Jun 17, 2024Stifel Nicolaus
Celldex initiated with a Buy at Stifel
Target:$58.00
+66.1%from $34.91
Nov 10, 2023Wells Fargo
Wells Fargo Upgrades Celldex Therapeutics (CLDX) to Equal Weight
Target:$27.00
+4.7%from $25.78
Nov 11, 2022Guggenheim
Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63
Target:$63.00
+57.9%from $39.89
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.